Details der Publikation - Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A

Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A

Abstract The in vitro antibacterial effect of a synthetic new peptide NJP9-A originated from natural marine invertebrates and its cytotoxicity, selectivity and one possible mechanism of action on human leukemia cells were investigated. NJP9-A showed significant bacteriostasis against Staphylococcus aureus (including methicillin-resistant S. aureus), and had a very low hemolysis efficiency on the human red blood cells. NJP9-A selectively bound to and inhibited the proliferation of leukemia cells, but had almost no inhibitory effect on the proliferation of HEK293 and HUVEC cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect may involve changing the expression of PIK3R1 (PI3K p85 regulatory subunit 1), and the corresponding PI3K signal transduction pathway. NJP9-A inhibits Gram-positive bacteria and is cytotoxic to leukemia cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect is still unclear, but it may be related to the alteration of PIK3R1 expression..

Medienart:	E-Artikel

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	Zur Gesamtaufnahme - volume:27
Enthalten in:	International journal of peptide research and therapeutics - 27(2021), 4 vom: 02. Juli, Seite 2199-2207

Sprache:	Englisch

Beteiligte Personen:	Ren, Kai [VerfasserIn] Chi, Xiumei [VerfasserIn] Wu, Tiange [VerfasserIn] Kan, Mujie [VerfasserIn] Liu, Jiankai [VerfasserIn] Cui, Jiayue [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie
Themen:	Gram-positive bacteria Leukemia cells Selectivity Synthetic peptide NJP9-A

Anmerkungen:	© The Author(s), under exclusive licence to Springer Nature B.V. 2021

doi:	10.1007/s10989-021-10246-4

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2128334632

Internformat


LEADER	01000naa a22002652 4500
001	OLC2128334632
003	DE-627
005	20230505144148.0
007	cr uuu---uuuuu
008	230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10989-021-10246-4 \|2 doi
035			\|a (DE-627)OLC2128334632
035			\|a (DE-He213)s10989-021-10246-4-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 540 \|q VZ
084			\|a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie \|2 bkl
100	1		\|a Ren, Kai \|e verfasserin \|4 aut
245	1	0	\|a Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Nature B.V. 2021
520			\|a Abstract The in vitro antibacterial effect of a synthetic new peptide NJP9-A originated from natural marine invertebrates and its cytotoxicity, selectivity and one possible mechanism of action on human leukemia cells were investigated. NJP9-A showed significant bacteriostasis against Staphylococcus aureus (including methicillin-resistant S. aureus), and had a very low hemolysis efficiency on the human red blood cells. NJP9-A selectively bound to and inhibited the proliferation of leukemia cells, but had almost no inhibitory effect on the proliferation of HEK293 and HUVEC cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect may involve changing the expression of PIK3R1 (PI3K p85 regulatory subunit 1), and the corresponding PI3K signal transduction pathway. NJP9-A inhibits Gram-positive bacteria and is cytotoxic to leukemia cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect is still unclear, but it may be related to the alteration of PIK3R1 expression.
650		4	\|a Leukemia cells
650		4	\|a Gram-positive bacteria
650		4	\|a Synthetic peptide NJP9-A
650		4	\|a Selectivity
700	1		\|a Chi, Xiumei \|4 aut
700	1		\|a Wu, Tiange \|4 aut
700	1		\|a Kan, Mujie \|4 aut
700	1		\|a Liu, Jiankai \|4 aut
700	1		\|a Cui, Jiayue \|0 (orcid)0000-0002-1034-9578 \|4 aut
773	0	8	\|i Enthalten in \|t International journal of peptide research and therapeutics \|d Springer Netherlands, 2005 \|g 27(2021), 4 vom: 02. Juli, Seite 2199-2207 \|h Online-Ressource \|w (DE-627)490716237 \|w (DE-600)2192632-3 \|w (DE-576)254902375 \|x 1573-3904 \|7 nnns
773	1	8	\|g volume:27 \|g year:2021 \|g number:4 \|g day:02 \|g month:07 \|g pages:2199-2207
856	4	0	\|u https://dx.doi.org/10.1007/s10989-021-10246-4 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2131
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie \|q VZ \|0 181571129 \|0 (DE-625)181571129
951			\|a AR
952			\|d 27 \|j 2021 \|e 4 \|b 02 \|c 07 \|h 2199-2207

Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände